Guardant Health's InfinityAI Real-World Evidence Supports Approval of ENHERTU® for Previously Treated Patients with HER2-Positive Metastatic Solid Tumors in Japan

Core Viewpoint - Guardant Health, Inc. has contributed real-world evidence through its InfinityAI platform, which played a role in the approval of ENHERTU® for treating HER2-positive advanced or recurrent solid cancers in Japan [1]. Group 1 - Guardant Health is recognized as a leading precision oncology company [1]. - The approval of ENHERTU® (trastuzumab deruxtecan) was developed and commercialized by Daiichi Sankyo [1]. - The treatment is specifically for patients with HER2-positive (HER2 [ERBB2] gene amplification or immunohistochemistry [IHC] 3+) advanced or recurrent solid cancers [1].